BackgroundThe Fibrosis-4 (FIB4) score, including age, transaminases and platelets, can detect severe fibrosis (F3-F4) in patients with Non Alcoolic Steato Hepatitis (NASH) and could be of interest in the follow-up of patients with RA. Indeed, platelets contribute to the pathophysiology of RA, transaminases are used in the liver monitoring of our treatments. In addition, retrospective data suggested the association between FIB4 and mortality in RA (1).ObjectivesWe aimed to evaluate the value of the FIB4 score as a prognostic factor in RA in the prospective ESPOIR cohort.MethodsPatients of the ESPOIR cohort diagnosed with RA according to ACR-EULAR criteria were included in our analysis. The formula for the FIB-4 score is as follows: [Age (years) × ASAT (U/L)] / [Platelet count (10^9/L) × ALT (U/L)1/2]. The analyses were based on linear mixed-effects models with a random effect on the subject to account for repeated measures throughout time.Results633 of the 813 patients included met the ACR/EULAR criteria for RA and had a calculable FIB4 score. Median FIB4 was 0.75 IQR (0.53-0.99) and 61 patients (9.6%) had a high FIB4 score at baseline. Baseline FIB4 was significantly higher in patients with a chronic alcohol consumption (p=0.021) or viral hepatitis (p<0.001). In multivariate analysis, including the main baseline prognostic factors for progression of RA (swollen Joint Count, CRP, Presence of ACPA, Rheumatoid Factor and modified Sharp score), FIB4 was not independently associated with progression of DAS28 during 10 years of follow-up, unlike baseline CRP and SJC. Baseline FIB4 was not associated with the modified Sharp score at 10-year follow-up unlike age and the presence of ACPA (Table 1). FIB4 was not associated with mortality (p=0.77) or major adverse cardiovascular events (p=0.22) during the 10-year follow-up. No significant change in FIB4 score over time was related to the use of NSAIDs, methotrexate, tocilizumab or other DMARDs.Table 1.Associations of FIB4 score with DAS28 and modified Sharp score evolutions in multivariate analysesVariableVariables included in modelp-valueDAS28Time<0.0001Age0.97Baseline number of swollen joints<0.0001Baseline Rheumatoid Factor0.51evolution over timeBaseline ACPA (presence)0.97Baseline CRP<0.0001Baseline modified Sharp score > 00.15Baseline FIB40.26Modified Sharp scoreTime0.052Age0.0005Baseline number of swollen joints0.38Baseline Rheumatoid Factor0.61evolution over timeBaseline ACPA (presence)0.012Baseline CRP0.84Baseline FIB40.25ConclusionOur study was the first to evaluate the value of FIB4 in a prospective cohort of RA patients. The present prospective cohort study with a 10-year follow-up did not find a prognostic role of FIB4 in RA, in contrast to previous retrospective studies. Reassuringly, FIB4 score was not increased by DMARD treatment after 10 years of follow-up, confirming the absence of long-term DMARD-related hepatotoxicity.References[1]Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong-Beom Park, Kwang-Hyub Han & Sang-Won Lee (2018): Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study, Modern Rheumatology, DOI: 10.1080/14397595.2018.1558760Figure 1.Impact of baseline FIB4 score on DAS28, HAQ and total modified-Sharp score over time.AcknowledgementsAn unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, Pfizer, Abbvie, Lilly, Sanofi also supported the ESPOIR cohort study.We also wish to thank Nathalie Rincheval (CHU Montpellier and EA 2415) who did expert monitoring and data management and all the investigators who recruited and followed the patients (F. Berenbaum, Paris-Saint Antoine, MC. Boissier, Paris-Bobigny, A. Cantagrel, Toulouse, B. Combe, Montpellier, M. Dougados, Paris-Cochin, P. Fardellone et P. Boumier Amiens, B. Fautrel, Paris-La Pitié, RM. Flipo, Lille, Ph. Goupille, Tours, F. Liote, Paris- Lariboisière, O. Vittecoq, Rouen, X. Mariette, Paris Bicetre, P. Dieude, Paris Bichat, A. Saraux, Brest, T. Schaeverbeke, Bordeaux, J. Sibilia, Strasbourg) V. Devauchelle and C Lukas for expert X-ray reading.Disclosure of InterestsNone declared.
BackgroundPrimary Sjögren’s syndrome (pSS) is a B-cell driven systemic auto-immune disease associated with the highest risk of lymphoma among systemic auto-immune diseases. In the prospective ASSESS cohort (395 patients enrolled, with a 10-year follow-up), transcriptomic analysis recently showed the association between baseline peripheral blood overexpression of Bruton’s tyrosine kinase (BTK) and lymphoma.ObjectivesThis study aimed to confirm the transcriptomic findings at the mRNA and protein level and to evaluate the relevance of BTK as a lymphoma predictor with regards to other predictors.MethodsBTK mRNA expression was assessed using qRTPCR in whole blood samples from 63 patients (12 patients with a history of lymphoma, 9 patients with incident lymphoma occurring during the 10-year follow-up, 21 patients without lymphoma and no risk factors for lymphoma and 21 patients without lymphoma and ESSDAI ≥ 5). BTK protein expression in peripheral blood was analyzed by flow cytometry in 7 healthy controls, 5 pSS patients without risk factors for lymphoma, 8 pSS patients with ESSDAI ≥5, and 6 pSS patients with lymphoma. In 346 patients of the ASSESS cohort for whom all data were available, the association between pSS-related lymphoma and BTK expression at enrolment, with 9 validated lymphoma predictors (parotid enlargement, purpura, ESSDAI ≥ 5, lymphocytopenia, CD4/CD8 ratio ≤ 0.8, RF positivity, cryoglobulinemia, monoclonal component, and low C4) and other potential biomarkers (serum FLT3L, BAFF, digital interferon alpha, gammaglobulins, IgG, beta2microglobulin, kappa and lambda free light chains, quantitative levels of anti-SSA/SSB) was analyzed. Multivariate analyses took into account in a first model, BTK and the 9 validated predictors of pSS-related lymphoma, and in a second model variables associated with lymphoma in univariate analysis selected by a stepwise procedure.ResultsIn qRTPCR, BTK was significantly upregulated between pSS patients with and without lymphoma. In flow cytometry, BTK protein expression in CD19+B cells (p=0.03), and in most B-cell subpopulations, was significantly increased in patients with lymphoma compared to healthy controls. A gradual increase was observed in BTK expression of CD19+B cells, between patients without risk factors for lymphoma, those with ESSDAI ≥5, and those with lymphoma. In multivariate analysis, taking into account 9 validated predictors of lymphoma in pSS, BTK expression at enrolment was significantly associated with lymphoma (adjusted OR [aOR] 1.45; 95% CI [1.19-1.82]; p<0.001), along with CD4/CD8 ratio ≤ 0.8 (aOR 6.03; 95% CI [1.23-26.13]; p=0.02). In a second model including 4 biomarkers selected by a stepwise procedure, BTK expression remained significantly associated with lymphoma (aOR 1.36; 95% CI [1.14-1.64]; p<0. 001), as well as serum BAFF levels (mean [SD]:1028.5 pg/ml [710.3]; per 1000 BAFF units, aOR 2.04; 95% CI [1.3-3.19]; p=0.001), low C4 (aOR 4.16; 95% CI [1.43-13.88]; p=0.01) and CD4/CD8 ratio ≤0.8 (aOR 10.62; 95% CI [2.49-44.15]; p=0.001).ConclusionThese results confirm that increased expression of BTK in peripheral blood is associated with pSS-related lymphoma. These results also show the potential interest of combining B-cell (BTK and BAFF) and T-cell (CD4/CD8 ratio)-related biomarkers to evaluate the risk of lymphoma in pSS.AcknowledgementsTo the patients for their participation to the ASSESS cohort; To the investigators of the ASSESS cohort; plateforme de transcriptomique de l’Institut Cochin; centre de ressources biologiques de l’Hôpital Bichat; The French Society of Rheumatology.Disclosure of InterestsPierre-Marie DURET: None declared, Cédric Schleiss: None declared, Nathanaël Sedmak: None declared, Nicolas Meyer: None declared, Tao Ye: None declared, Lou Kawka: None declared, Alain Saraux: None declared, Valerie Devauchelle-Pensec: None declared, Divi Cornec: None declared, Claire Larroche: None declared, Aleth Perdriger: None declared, Raphaèle Seror: None declared, Renaud FELTEN: None declared, Jean Sibilia: None declared, Gaetane Nocturne: None declared, Xavier Mariette Consultant of: Astra Zeneca, BMS, Galapagos, GSK, Novartis, Pfizer, Jacques-Eric Gottenberg Consultant of: Astra Zeneca, BMS, Galapagos, GSK, Novartis, Pfizer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.